Filing identity and reporting period
Important identification issue: The supplied filing is Ziopharm Oncology, Inc.’s Form 10-K for the fiscal year ended December 31, 2020, filed March 1, 2021. It is not identified in the filing as Alaunos Therapeutics, Inc. The “2020 Q4” metadata is not the filing period; the filing includes full-year results and unaudited fourth-quarter data.
Ziopharm was a clinical-stage immuno-oncology company developing cell and gene therapies. Its priorities included the non-viral Sleeping Beauty platform for TCR-T and CAR-T programs, and a Controlled IL-12 platform.
Financial results and liquidity
| Metric | FY 2020 | FY 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $52.7 million | $38.3 million |
| General and administrative expense | $27.7 million | $19.5 million |
| Total operating expenses | $80.4 million | $57.9 million |
| Net loss | $80.0 million | $117.8 million |
| Basic and diluted loss per share | $0.38 | $0.70 |
| Net cash used in operating activities | $57.0 million | $40.9 million |
| Capital expenditures | $9.8 million | $0.3 million |
Fourth-quarter 2020 revenue was $0; operating expenses were $22.8 million and net loss applicable to common shareholders was $22.8 million, or $0.11 per share.
- Cash and cash equivalents were $115.1 million at year-end, up from $79.7 million. Working capital was $112.2 million, versus $93.0 million.
- Financing provided $102.1 million in 2020, principally from a public offering and at-the-market share sales. The company reported 214.6 million common shares outstanding at year-end; 214.7 million were reported as of February 24, 2021.
- Total liabilities were $22.4 million, including $4.8 million in lease liabilities. The balance sheet shows no borrowings or other financial debt.
- Management estimated existing cash would fund operations into the second quarter of 2022, while warning that estimates could vary and that no additional capital was committed.
Margins are not meaningful to assess as the company reported no revenue. The filing reports no dividends.
Material changes and unusual items
- Operating expenses rose 39% year over year, with R&D up 37% and G&A up 42%. Management attributed R&D growth mainly to increased staffing, manufacturing and trial support, and facility buildout; G&A growth primarily reflected advisory and other professional services.
- Net loss narrowed from 2019, but 2019 included a $60.8 million non-cash inducement warrant expense. Operating expenses and operating cash use both increased in 2020.
- Cash flow from financing supported the higher cash balance. The 2020 public offering generated approximately $88.7 million net, and at-the-market sales generated approximately $13.0 million net.
- Capital spending increased substantially as the company built out laboratory and manufacturing-related facilities in Houston.
- The filing identifies 2018’s $207.4 million related-party settlement credit as a material one-time item affecting that year’s reported income; it is not a recurring operating result.
Outlook, programs, and risks
- Management planned to prioritize the Sleeping Beauty TCR program and reduce spending on Controlled IL-12 in 2021, while seeking a partner to support that program’s continued development.
- The FDA cleared the company-sponsored Library TCR-T Phase 1/2 IND in February 2021, after year-end; management expected dosing to begin in the second half of 2021. The NCI’s Personalized TCR-T trial had temporarily suspended enrollment for reasons described as internal to the NCI.
- Eden BioCell received Taiwan FDA clearance in Q4 2020 for a Phase 1 CD19 CAR-T trial. In the United States, an MD Anderson-led CAR-T trial was underway, with patients expected to be dosed upon cancer progression.
- Controlled IL-12 adult glioblastoma studies were enrolled, with dosing ongoing in a combination study. Reported interim survival and response observations came from small patient groups and are not definitive evidence of efficacy. The pediatric brain-tumor trial had dosed its first patient in 2020.
- Key risks include continued cash burn and need for additional financing; clinical, regulatory, manufacturing and trial-enrollment uncertainty; reliance on third parties and licensors; COVID-19 disruption; and competition. A prior material weakness in controls over clinical-trial cost accruals was reported as remediated at December 31, 2020, and the auditor issued an unqualified opinion on internal control.
- Leadership changed after year-end: the CEO and CFO positions had interim appointments, and the company said it was searching for permanent replacements. The filing also describes stockholder activism and board changes.
Important facts for investors to verify
- Confirm the issuer and filing: the supplied document is Ziopharm’s 2020 Form 10-K, not an Alaunos Therapeutics filing.
- Review the audited financial statements and cash-flow assumptions underlying the stated runway into Q2 2022, including subsequent financing and spending.
- Track share issuance, outstanding warrants and options, and the limited authorized common-share capacity; the filing cites substantial shares reserved for options and warrants.
- Verify trial enrollment, dosing, safety and mature efficacy data for the TCR-T, CAR-T and Controlled IL-12 programs, distinguishing interim observations from final results.
- Assess whether the planned Controlled IL-12 spending reduction or potential partnership changes program timelines, data collection or development prospects.
- Monitor leadership transitions, third-party and license obligations, and the company’s continued effectiveness of controls over clinical-trial accruals.